FIELD: biotechnology.
SUBSTANCE: the invention relates to biotechnology and immunogenic compositions containing plasmid for expression of membrane antigen of hepatitis B virus (HBsAg). The said plasmid includes: (1) the sequence which encodes HBsAg, which has an aminoacid sequence SEQ ID NO:3; (2) a promoter of the glyceralgehyde-3-phosphate dehydrogenase, positioned above, to control the expression of the sequence which encodes HBsAg, and the promoter contains a gene sequence SEQ ID NO:1; and (3) the transcription terminator ARG3, positioned below the sequence which encodes HBsAg, where the terminator includes SEQ ID NO:8.
EFFECT: HBsAg can be purified and used to produce vaccines and, in particular, in production of monovalent and combined vaccines.
40 cl
Authors
Dates
2012-02-20—Published
2006-04-14—Filed